Fig. 2
From: IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL
Survival analyses adjusted according to therapy, extranodal sites and stages. Patients with DLBCL were separated into two groups according to the mRNA expression of IQGAP2 in every figure. Survival analyses of all patients in the GSE10846 (a) and GSE11318 (b) datasets. Survival analyses of patients treated with CHOP (c and d) or R-CHOP (e). Survival analyses of patients with extranodal sites > 1 (f) or ≤ 1 (g, h). Survival analyses of patients with Ann Arbor stage III/IV (i and j) or I/II (k and l). AAS, Ann Arbor stage